EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Mabpharm's enterprise value is HK$1,518.26 Mil.
Mabpharm's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$95.34 Mil. Therefore, Mabpharm's EV-to-Revenue for today is 15.93.
The historical rank and industry rank for Mabpharm's EV-to-Revenue or its related term are showing as below:
HKSE:02181'
s EV-to-Revenue Range Over the Past 10 Years
Min: 13.54 Med: 29.79 Max: 50.92
Current: 16.79
During the past 7 years, the highest EV-to-Revenue of Mabpharm was 50.92. The lowest was 13.54. And the median was 29.79.
HKSE:02181's EV-to-Revenue is ranked worse than 63.2% of 1038
companies
in the Biotechnology industry
Industry Median: 7.985
vs HKSE:02181: 16.79
As of today (2024-06-05), Mabpharm's stock price is HK$0.365.
Mabpharm's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.02. Therefore, Mabpharm's PS Ratio for today is 15.87.
Mabpharm EV-to-Revenue Historical Data
The historical data trend for Mabpharm's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Mabpharm's EV-to-Revenue
For the Biotechnology subindustry, Mabpharm's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mabpharm's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mabpharm's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Mabpharm's EV-to-Revenue falls into.
Mabpharm's current Enterprise Value is HK$1,518.26 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Mabpharm's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$95.34 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mabpharm's share price for today is HK$0.365.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.02.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mabpharm EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Mabpharm's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Mabpharm Ltd is a biopharmaceutical company. The company is engaged in the research, development, and production of new drugs and biosimilars for cancers and autoimmune diseases. Its core products include CMAB008 (infliximab), CMAB007 (omalizumab), and CMAB009 (cetuximab).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02181 has been successfully added to your 